Target
axitinib
8 abstracts
Abstract
Lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial.Org: University Hospital Essen, Memorial Sloan Kettering Cancer Center, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Department of Urology and Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany, Medical University of Vienna,
Abstract
Avelumab with axitinib in persistent or recurrent cervical cancer after platinum-based chemotherapy (ALARICE study).Org: Department of Obstetrics and Gynaecology, Pokfulam, Yaumatei, Pamela Youde Nethersole Eastern Hospital, Chai Wan,
Abstract
Phase II clinical study of the safety and efficacy of sintilimab in combination with axitinib and stereotactic radiotherapy in the treatment of local-regional recurrent renal cell cancer.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Axitinib in combination with anti–PD-1 ab (pucotenlimab) plus intra-hepatic injection of oncolytic virus (OH2), in patients with mucosal melanoma and liver metastasis: An open-label phase I trial.Org: Department of Melanoma and Sarcoma Oncology,
Abstract
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.Org: Vanderbilt-Ingram Cancer Center, Russian Scientific Center of Roentgenoradiology, Central Clinical Hospital With Outpatient Clinic, Centre Hospitalier de l’Université de Montréal, Hospital de Clínicas de Porto Alegre,
Abstract
Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study.Org: Mount Vernon Cancer Center, Northwood, United Kingdom, Christie NHS Foundation Trust, Manchester, United Kingdom, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Royal Preston Hospital,
Abstract
Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma.Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China, West China Hospital, Sichuan University, Chengdu, China, Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya Medical School, Central South University, Changsha, China,
Abstract
Use of immunotherapy-based combos in advanced renal cell carcinoma in a Galician center.Org: Servicio de Oncologia Medica, Hospital Universitario de Santiago, Santiago De Compostela, Spain, Medical Oncology Department, Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain, Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain, Department of Oncologic Pharmacy, Santiago de Compostela University Hospital, Santiago De Compostela, Spain, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), Santiago De Compostela, Spain,